Lilly.com | Eli Lilly and Company
Dec 17, 2024 · Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
All News - Eli Lilly and Company
Lilly's latest press releases, stories, news resources and more.
Lilly announces $3 billion expansion of its recently acquired ...
Dec 5, 2024 · Lilly will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production. From data management to operations, digital automation will be embedded throughout the site to accelerate processes and increase accuracy, allowing employees to focus on making safe, high-quality medicines.
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high ...
Nov 18, 2024 · For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events ...
Lilly commends ITC ruling cracking down on the unlawful …
Dec 23, 2024 · News Release Lilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk. December 23, 2024 Download PDF 449.5 KB. Evidence of harmful knockoff tirzepatide escalates . INDIANAPOLIS, December 23, 2024 – In a win for patients, the judge overseeing Lilly’s ...
Lilly.com | Eli Lilly and Company
Nov 19, 2024 · INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge , M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024 .
Eli Lilly and Company (LLY) Latest Stock News & Headlines
Get the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
Aug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Lilly reports Q3 2024 financial results highlighted by strong …
Oct 30, 2024 · Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024.
Eli Lilly and Company (LLY) Latest Press Releases & Corporate News …
Get the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.